A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib
Concomitant mutations of echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) can be found rarely in lung adenocarcinoma. We present a case of harboring EML4/ALK rearrangement lung adenocarcinoma who previo...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2018-08-01
|
| Series: | Journal of Oncological Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336417301085 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839598201895649280 |
|---|---|
| author | Mehmet Artaç Levent Korkmaz Mustafa Karaağaç Buğra Kaya Necdet Poyraz Hakan Özön Zehra Er Lema Tavlı |
| author_facet | Mehmet Artaç Levent Korkmaz Mustafa Karaağaç Buğra Kaya Necdet Poyraz Hakan Özön Zehra Er Lema Tavlı |
| author_sort | Mehmet Artaç |
| collection | DOAJ |
| description | Concomitant mutations of echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) can be found rarely in lung adenocarcinoma. We present a case of harboring EML4/ALK rearrangement lung adenocarcinoma who previously received erlotinib. A 42-year-old male who was diagnosed as lung adenocarcinoma and received many series of cytotoxic regimens. A partial tumor response was achieved with crizotinib after failure with erlotinib therapy. After progressive disease, biopsy of new liver lesion showed EML4/ALK rearrangement. Thus crizotinib was administrated. A partial tumor response was achieved with crizotinib after failure with erlotinib therapy and chemotherapy. We conclude that it is important to evaluate for EML4/ALK rearrangement even the patient has EGFR mutation. Concomitant EGFR exon 18 and EML4-ALK mutations can occur in lung adenocarcinoma. EML4/ALK related TKIs may be more effective in these patients. Keywords: Non-small cell lung cancer, Erlotinib, Epidermal growth factor receptor, Anaplastic lymphoma kinase, Crizotinib |
| format | Article |
| id | doaj-art-b51e5cc167bc474092100efa8a5e8bba |
| institution | Matheson Library |
| issn | 2452-3364 |
| language | English |
| publishDate | 2018-08-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Journal of Oncological Sciences |
| spelling | doaj-art-b51e5cc167bc474092100efa8a5e8bba2025-08-02T17:20:19ZengGalenos Publishing HouseJournal of Oncological Sciences2452-33642018-08-0142111113A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinibMehmet Artaç0Levent Korkmaz1Mustafa Karaağaç2Buğra Kaya3Necdet Poyraz4Hakan Özön5Zehra Er6Lema Tavlı7Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, Turkey; Corresponding author. Necmettin Erbakan University, Meram Medical Faculty, Department of Medical Oncology, 42080, Konya, Turkey.Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Nuclear Medicine, Konya, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Radiology, Konya, TurkeyIstanbul Genetics Laboratory, Istanbul, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Pathology, Konya, TurkeyConcomitant mutations of echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) can be found rarely in lung adenocarcinoma. We present a case of harboring EML4/ALK rearrangement lung adenocarcinoma who previously received erlotinib. A 42-year-old male who was diagnosed as lung adenocarcinoma and received many series of cytotoxic regimens. A partial tumor response was achieved with crizotinib after failure with erlotinib therapy. After progressive disease, biopsy of new liver lesion showed EML4/ALK rearrangement. Thus crizotinib was administrated. A partial tumor response was achieved with crizotinib after failure with erlotinib therapy and chemotherapy. We conclude that it is important to evaluate for EML4/ALK rearrangement even the patient has EGFR mutation. Concomitant EGFR exon 18 and EML4-ALK mutations can occur in lung adenocarcinoma. EML4/ALK related TKIs may be more effective in these patients. Keywords: Non-small cell lung cancer, Erlotinib, Epidermal growth factor receptor, Anaplastic lymphoma kinase, Crizotinibhttp://www.sciencedirect.com/science/article/pii/S2452336417301085 |
| spellingShingle | Mehmet Artaç Levent Korkmaz Mustafa Karaağaç Buğra Kaya Necdet Poyraz Hakan Özön Zehra Er Lema Tavlı A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib Journal of Oncological Sciences |
| title | A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib |
| title_full | A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib |
| title_fullStr | A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib |
| title_full_unstemmed | A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib |
| title_short | A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib |
| title_sort | lung adenocarcinoma patient with egfr mutation in exon 18 and alk rearrangement who treated with erlotinib and crizotinib |
| url | http://www.sciencedirect.com/science/article/pii/S2452336417301085 |
| work_keys_str_mv | AT mehmetartac alungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT leventkorkmaz alungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT mustafakaraagac alungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT bugrakaya alungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT necdetpoyraz alungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT hakanozon alungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT zehraer alungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT lematavlı alungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT mehmetartac lungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT leventkorkmaz lungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT mustafakaraagac lungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT bugrakaya lungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT necdetpoyraz lungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT hakanozon lungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT zehraer lungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib AT lematavlı lungadenocarcinomapatientwithegfrmutationinexon18andalkrearrangementwhotreatedwitherlotinibandcrizotinib |